What is Enveda Biosciences?
AI-powered drug discovery company mining natural products for new medicines.
- Category
- AI drug discovery
- Headquarters
- Boulder, Colorado
- Founded
- 2019
- Employees
- Private; U.S. and India R&D teams
- Total funding
- More than $360 million disclosed
- Status
- Private
What is Enveda Biosciences?
Enveda Biosciences is a ai drug discovery company headquartered in Boulder, Colorado.
Enveda uses machine learning, metabolomics, and large natural-product datasets to discover and develop small-molecule medicines. The company is building an internal clinical pipeline and has reported multiple discovery programs; revenue/customer counts are not public.
The company was founded in 2019 and remains private. Its public profile is strongest around PRISM platform and Metabolomics data engine, while detailed revenue figures are not publicly disclosed.
As of June 2026, the safest public read is that Enveda Biosciences is scaling through enterprise partnerships and capital-intensive product development rather than a self-serve consumer motion.
Sources:Enveda websiteEnveda news
What does Enveda Biosciences offer?
Enveda Biosciences's public product set centers on PRISM platform, Metabolomics data engine, Internal clinical pipeline.
- PRISM platform· Natural products AI
- Metabolomics data engine· Data platform
- Internal clinical pipeline· Drug development
- Medicinal chemistry workflows· R&D
Sources:Enveda website
How does Enveda Biosciences make money?
Biotech pipeline model with value from internal programs, partnerships, and future milestones; no software pricing is public.
Biotech pipeline model with value from internal programs, partnerships, and future milestones; no software pricing is public. No public list pricing; therapeutics company.
Growth is driven by enterprise adoption, strategic partnerships, and proof that the platform can deliver measurable operational, clinical, scientific, or mission outcomes. Because Enveda Biosciences does not publish standard list prices, buyers should treat budget sizing as a custom-contract exercise.
The commercial motion therefore depends on executive sponsorship, security and compliance review, and evidence that the product can integrate into existing workflows rather than replace them all at once.
Who leads Enveda Biosciences?
Enveda Biosciences is led by Viswa Colluru, Founder and CEO.
- Viswa ColluruFounder and CEOFounder · since 2019Founded Enveda to industrialize natural-product drug discovery.
- Daphne KollerBoard/investorBoardAI drug discovery leader and investor involved in company governance.
- Kinnevik / FPV representativesInvestorsInvestorsGrowth investors supporting platform and pipeline scale.
How do you contact Enveda Biosciences's leadership?
Public contact form; no verified personal email pattern found. Use the listed public company route rather than guessed personal inboxes.
Public contact form; no verified personal email pattern foundSources:Enveda website
How much funding has Enveda Biosciences raised?
Enveda Biosciences has more than $360 million disclosed and is private.
2021: Series A — $51 million, led/backed by Lux Capital and others. 2022: Series B — $68 million, led/backed by Dimension and others. 2024: Series C — $55 million, led/backed by Premji Invest and others. 2025: Series D — $150 million, led/backed by Kinnevik and FPV Ventures (Valuation undisclosed).
The latest public valuation/status marker is Undisclosed. Where a valuation is undisclosed, public reporting only supports the financing amount and participating investors.
Funding is best interpreted as capacity for product build-out, hiring, regulatory or deployment work, and longer sales cycles; it should not be read as proof of profitability unless the company has separately disclosed profitability.
How did Enveda Biosciences get here?
Enveda Biosciences's timeline runs from its 2019 founding through major financing and product milestones.
- 2019FoundedEnveda was founded in Boulder to discover medicines from natural chemistry.
- 2021Series AThe company raised $51 million to build its platform.
- 2022Series BEnveda expanded data and discovery operations.
- 2024Series CThe company financed clinical pipeline development.
- 2025Series DEnveda raised $150 million to advance programs.
Sources:Enveda websiteEnveda news
Who are Enveda Biosciences's competitors?
Enveda Biosciences competes with specialized startups and larger platform companies in ai drug discovery.
Enveda Biosciences — frequently asked questions
